NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
13F holders, Q3 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- 0 vs. Q2 2023
- Shares held
- 1.55M
- +62.6K (+4.2%) vs. Q2 2023
- Total value
- $2.88M
- −$1.06M (−26.9%) vs. Q2 2023
- New holders
- 1
- 1 more added
- Sold out
- 1
- 3 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMSW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $28.1M |
| Q1 2026 | 9 | $26.0M |
| Q4 2025 | 9 | $29.9M |
| Q3 2025 | 9 | $22.2M |
| Q2 2025 | 10 | $10.4M |
| Q1 2025 | 10 | $12.3M |
| Q4 2024 | 11 | $18.8M |
| Q3 2024 | 11 | $9.32M |
| Q2 2024 | 10 | $11.5M |
| Q1 2024 | 11 | $15.9M |
| Q4 2023 | 18 | $4.91M |
| Q3 2023 | 19 | $2.88M |
| Q2 2023 | 19 | $3.94M |
| Q1 2023 | 19 | $4.12M |
| Q4 2022 | 22 | $1.91M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 1 | $35.5K |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 38 | $72 | 0.00% | +38 | New |
| Cutler Group LP | 4,960 | $9.00K | 0.00% | 00.0% | Unchanged |
| Vestcor Inc | 9,632 | $18.0K | 0.00% | 00.0% | Unchanged |
| Exos TFP Holdings LLC | 12,273 | $23.3K | 0.01% | −10,000−44.9% | Reduced |
| Walleye Trading LLC | 13,084 | $24.9K | 0.00% | −5,400−29.2% | Reduced |
| Clear Street LLC | 13,463 | $25.6K | 0.00% | 00.0% | Unchanged |
| Laurion Capital Management LP | 16,666 | $31.7K | 0.00% | 00.0% | Unchanged |
| PEAK6 Investments LLC | 17,000 | $32.3K | 0.00% | 00.0% | Unchanged |
| Walleye Capital LLC | 22,658 | $43.0K | 0.00% | −9,600−29.8% | Reduced |
| Westchester Capital Management, LLC | 31,189 | $54.6K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 30,321 | $57.0K | 0.00% | 00.0% | Unchanged |
| Highbridge Capital Management LLC | – | $92.1K | 0.01% | – | – |
| Deerfield Management Company, L.P. (Series C) | 92,787 | $176.3K | 0.00% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 100,000 | $190.0K | 0.02% | 00.0% | Unchanged |
| Ensign Peak Advisors, Inc | 150,000 | $255.0K | 0.00% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 137,000 | $260.3K | 0.09% | +100,000+270.3% | Added |
| Ra Capital Management, L.P. | 333,333 | $633.3K | 0.01% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 500,333 | $950.6K | 0.06% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 66,665 | – | – | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −12,448−100.0% | Sold out |